-
-
-
-
-
-
-
Citi Opens 30-Day Upside Catalyst Watch on EyePoint Inc. (EYPT)
-
-
-
-
-
-
-
EyePoint Inc. (EYPT) PT Raised to $29 at Chardan
-
-
-
-
-
-
-
EyePoint advances retinal drug trials with 2026 data readouts expected
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
-
-
-
-
-
-
EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $26 at Mizuho
-
-
-
-
-
-
-
EyePoint Pharmaceuticals' (EYPT) decline "makes no sense", says Cantor Fitzgerald
-
-
-
-
-
-
-
EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright
-
434,555 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

